蔚蓝生物：公司目前设有1个合成生物与生物催化技术中心

Core Viewpoint - The company, Weilan Bio (603739), is currently in the early stages of developing synthetic biology products, with significant challenges ahead in terms of commercialization and industrialization [1] Group 1: Research and Development - The company has established a synthetic biology and biocatalysis technology center, which includes an innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] - The current R&D projects in the synthetic biology technology innovation laboratory are limited, with low investment amounts and insufficient professional personnel [1] - The laboratory is still in the preliminary strain research phase, indicating a considerable gap before achieving large-scale production [1] Group 2: Production Challenges - The production of synthetic biology products involves complex processes such as separation and purification, which the company currently lacks the capability to perform [1] - There are significant uncertainties regarding the commercialization of these products, which may also require regulatory approvals and market promotion, leading to a lengthy and challenging process [1] Group 3: Impact on Operations - The company anticipates that the current developments in synthetic biology will not have a significant impact on its operations in the foreseeable future [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations and will provide timely updates through official announcements [1]